Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q3 2022 · 10-Q
Revenue$26.56M$26.56M+14.3% vs Q3 2021 Net Income-$41.91M-$41.91MN/M vs Q3 2021 EPS Diluted-$0.38-$0.38N/M vs Q3 2021 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flowderived-$37,066,000N/M Free Cash Flowderived-$37,111,000N/M Margins · derivedGross margin44.6%
Operating margin-157.7%+64.9 pt vs Q3 2021
Net margin-157.8%+67.8 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 8, 2022 · 39 d after period end